Pharmaceutical firm Wasdell has further ramped up its contribution to combating the pandemic.
The Swindon-based pharmaceutical manufacturing and packaging firm has been producing antiseptic and disinfectant products for a major global brand since the early days of covid.
Wasdell has also been appointed to support production of ribonucleic acid (RNA) extraction kits for use in PCR tests. The work includes the manufacturing, filling, secondary packaging and transporting of up to 1.8m 0.5ml vials of buffer fluid per week.
Wasdell Sales Director Andy Causer said the company’s ability to demonstrate it could support the requirements for extraction kits very rapidly was a key element in securing the contract.
He added: “As an independent company we have built a strong reputation for being fleet of foot and responsive,” said Causer.
“The customer’s requirements were necessarily quite complex, and included the freezing, defrosting and refreezing of the product under controlled conditions. We worked closely with the client to find solutions for their various challenges, and the period from receipt of instructions to roll out of the first batch was just four weeks.”
Wasdell also had to overcome supply chain issues, as national shortages of materials developed and sourcing alcohol, plastic bottles and vials became more difficult.